23:31:35 EDT Thu 24 Sep 2020
Enter Symbol
or Name

Login ID:
Microbix Biosystems Inc
Symbol MBX
Shares Issued 108,747,705
Close 2020-05-07 C$ 0.345
Recent Sedar Documents

Microbix releases COVID-19 QAPs to U.S. labs

2020-05-07 09:34 ET - News Release

Mr. Cameron Groome reports


Microbix Biosystems Inc. has made available in the United States its SARS-CoV-2 quality assessment products (QAP) -- Food and Drug Administration registration enabling immediate usage by U.S. clinical laboratories to evaluate performance, procedures and workflow of tests that detect SARS-CoV-2 virus, the causative agent of the COVID-19 disease.

Microbix has registered with the U.S. FDA in compliance with Code of Federal Regulations 21, Part 807, augmenting its existing establishment registration No. 3007652384. This permits sale of its SARS-CoV-2 positive and negative controls throughout the U.S. and its territories.

It has been widely reported that the recently deployed tests for the virus causing COVID-19 disease are providing results of questionable accuracy -- sometimes giving false negative, or false positive, results. Microbix's SARS-CoV-2 QAPs are designed to increase the reliability of nucleic-acid test (NAT) results. These Microbix QAPs can be used to support verification of new testing methods, validation of newly placed test instruments, training of technicians, lab proficiency accreditations and by clinical labs for systematic quality control.

Cameron Groome, president and chief executive officer, stated: "We're pleased to have completed the process of registering our SARS-CoV-2 controls to permit their sale as controls to clinical labs in the United States. Microbix will now engage with American laboratory chains, group purchasing organizations and procurement agencies to make certain that the U.S. health care system can benefit from Microbix's products that help to ensure test accuracy."

The Microbix COVID-19 QAPs have been shown to work with multiple NAT methods used to detect the SARS-CoV-2 virus that causes COVID-19 disease, specifically tests targeting a variety of nucleic-acid targets across the genome of the virus. These Microbix products are being made available as REDx FLOQ SARS-CoV-2 for swabs and as REDx SARS-CoV-2 for liquid aliquots.

As for all Microbix QAPs, these COVID-19 QAPs are whole-genome workflow support tools that include 100 per cent of the genetic sequences of the virus and emulate real patient samples while being consistent, non-infectious and stable. As such, the COVID-19 QAPs contain all known potential NAT viral targets -- ensuring compatibility across current and future NATs. This broad compatibility and guaranteed utility is particularly relevant in the context of testing during a pandemic, when multiple test protocols and instrument systems are being newly called into use.

Microbix supplies a broad range of white-labelled QAPs, including other viral respiratory pathogens, to support the proficiency testing (PT) programs of laboratory accreditation organizations in North America, Western Europe and Scandinavia. Under its PROCEEDx brand, Microbix provides research-use-only (RUO) QAPs to support the test validation/verification and operator training objectives of test developers and clinical labs. Full QMS support of clinical laboratory patient sample testing is provided by Microbix's REDx controls or REDx FLOQ brand QAPs.

About Microbix Biosystems Inc.

Microbix develops proprietary biological and technology solutions for human health and well-being, with approximately 80 skilled employees and sales now usually exceeding $1-million per month on average. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory-quality assessment products that support clinical lab proficiency testing, enable assay development and validation, or help ensure quality control of clinical diagnostic tests.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.